CD56在多发性骨髓瘤预后及进展中的意义  

作　　者：王思琦 陈素峰[2] 王剑超 王贞贞 彭佳敏 

机构地区：[1]浙江中医药大学,310053 [2]浙江省人民医院,310014 [3]浙江省立同德医院,310012

出　　处：《浙江临床医学》2024年第4期575-577,共3页Zhejiang Clinical Medical Journal

基　　金：浙江省自然科学基金资助项目(Y23H290020)。

摘　　要：目的分析CD56表达在多发性骨髓瘤(MM)预后及进展中的价值。方法根据CD56表达情况将53例MM患者分为阳性、阴性,比较两组一般临床资料和实验室指标。结果CD56阴性MM患者伴髓外病变的发生概率较CD56阳性患者明显增加(P=0.027),CD56阴性和CD56阳性PFS和OS差异均有统计学意义(P<0.05);初诊时LDH升高是MM患者不良PFS的一个独立危险因素(P=0.037)。结论MM患者中CD56的表达对是否发生髓外病变、浆细胞白血病转化及预测PFS有一定的临床价值。Objective To analyze the value of CD56 expression in the prognosis and progression of multiple myeloma(MM).Methods According to CD56 expression,53 MM patients were divided into the positive and the negative groups.The general clinical data and laboratory indexes of the two groups were compared.Results The probability of the occurrence of extramedullary infiltration was significantly higher in the CD56-MM patients compared with that of the CD56+patients(P=0.027).There was s statistically significant difference in PFS and OS between the two groups(P<0.05).elevated LDH at the initial diagnosis was an independent risk factor for poor PFS in MM patients(P=0.037).Conclusion CD56 expression in MM has some clinical value on whether plasma cell extramedullary lesions occur,plasma cell leukemia transformation,and PFS in MM patients.

关 键 词：CD56 多发性骨髓瘤 预后 进展 浆细胞白血病 

分 类 号：R733.3[医药卫生—肿瘤]